Natera's Multi-Cancer Early Detection Assay Granted FDA Breakthrough Device Designation

MT newswire2026/10/09 12:24

08:24 AM EDT, 10/09/2026 (MT Newswires) -- Natera's (NTRA) multi-cancer early detection assay has been granted Breakthrough Device Designation by the US Food and Drug Administration, the genetic testing company said Friday. The multi-cancer early detection assay works by analyzing cell-free DNA in the blood to screen for multiple cancers, according to a statement. The designation is intended to speed up development, assessment, review, as well as marketing authorization of medical devices, Natera said.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Dana Gas reports suspected drone attack on Iraq Kurdistan Khor Mor gas field, production halted

智通财经•2026/11/09 05:16

Earnings Preview | Applied Materials (AMAT.US) Q4 Results are Certain, the Real Focus is on the Missing 2027 Quantitative Guidance

Applied Materials' high growth in revenue and profit this quarter is already certain. What truly determines the stock price is the guidance for fiscal year 2027, changes in gross margin, and the marginal changes in China-related risks.

智通财经•2026/11/09 04:37

Earnings Preview | Applied Materials (AMAT.US) Q4 Results Hold No Surprises; The Real Focus Is the Yet-to-be-Given 2027 Quantitative Guidance

智通财经•2026/11/09 04:36

Nomura’s dominance is being challenged! Mizuho (MFG.US) is reshaping Japan’s underwriting landscape with global IPOs

智通财经•2026/11/09 03:51